654663-42-0 Usage
Description
2-[4-(tert-Butoxycarbonyl)piperazin-1-yl]isonicotinic acid is a chemical compound with the molecular formula C15H22N4O4. It belongs to the class of piperazine derivatives and isonicotinic acid derivatives. This versatile intermediate is commonly used in medicinal chemistry for the synthesis of potential drug candidates due to its ability to be further modified to introduce different functional groups, allowing for the creation of diverse pharmacologically active compounds. The presence of the tert-Butoxycarbonyl (Boc) protecting group in the molecule enables selective deprotection under specific conditions, making it a valuable tool in organic synthesis. The piperazine moiety also imparts potential biological activity, rendering this compound a promising candidate for further drug development.
Uses
Used in Pharmaceutical Industry:
2-[4-(tert-Butoxycarbonyl)piperazin-1-yl]isonicotinic acid is used as a building block for the synthesis of potential drug candidates, particularly for the development of new medications targeting various diseases and conditions. Its versatility in organic synthesis and the presence of the Boc protecting group make it an ideal candidate for the creation of a wide range of pharmacologically active compounds.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-[4-(tert-Butoxycarbonyl)piperazin-1-yl]isonicotinic acid is used as a versatile intermediate for the design and synthesis of novel compounds with potential therapeutic applications. Its ability to be modified and functionalized allows researchers to explore new chemical entities that may exhibit improved efficacy, selectivity, and safety profiles compared to existing drugs.
Used in Organic Synthesis:
2-[4-(tert-Butoxycarbonyl)piperazin-1-yl]isonicotinic acid is utilized as a valuable tool in organic synthesis, particularly for the selective deprotection of the Boc group under specific conditions. This feature enables chemists to control the reactivity and stability of the compound during the synthesis process, facilitating the development of complex molecular structures with tailored properties.
Used in Drug Development:
The presence of the piperazine moiety in 2-[4-(tert-Butoxycarbonyl)piperazin-1-yl]isonicotinic acid endows it with potential biological activity, making it a promising candidate for drug development. Researchers can leverage this compound's inherent pharmacological properties to design and optimize new drugs with improved therapeutic effects and reduced side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 654663-42-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,5,4,6,6 and 3 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 654663-42:
(8*6)+(7*5)+(6*4)+(5*6)+(4*6)+(3*3)+(2*4)+(1*2)=180
180 % 10 = 0
So 654663-42-0 is a valid CAS Registry Number.
InChI:InChI=1/C15H21N3O4/c1-15(2,3)22-14(21)18-8-6-17(7-9-18)12-10-11(13(19)20)4-5-16-12/h4-5,10H,6-9H2,1-3H3,(H,19,20)
654663-42-0Relevant articles and documents
DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
-
Paragraph 0959; 0961, (2019/05/15)
Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activa
6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
-
Paragraph 0777; 0779, (2019/05/08)
Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
